Browse Articles

Filter By:

  • Limited information exists regarding the effects of prostate cancer therapies on sexual health outcomes in sexual and gender minority patients. As clinicians, scientists and advocates, understanding these outcomes is imperative in order to enable personalized clinical decision-making and to create a more equitable health system.

    • Daniel R. Dickstein
    • Deborah C. Marshall
  • Patients with prostate cancer from sexual minority groups experience considerably worse quality of life following prostate cancer treatment than heterosexual patients. Improved inclusivity as well as cultural humility training at the physician, institution and system levels are warranted to address inequalities in quality-of-life outcomes.

    • David J. Benjamin
    • Arash Rezazadeh
  • Since calcium/calmodulin-dependent kinase kinase 2 (CAMKK2) was identified as an androgen-receptor-regulated gene, important functional roles of CAMKK2 in prostate cancer progression have been shown in preclinical models. In this Perspective, the authors present evidence supporting an oncogenic role of CAMKK2, and also discuss mechanisms of regulation and emerging non-cell-autonomous roles of CAMKK2. Moreover, the potential use of CAMKK2 as a biomarker and/or therapeutic target in prostate cancer is discussed.

    • Thomas L. Pulliam
    • Pavithr Goli
    • Daniel E. Frigo
  • In this Review, Russo and Giri describe and discuss germline testing criteria, genetic testing strategies, genetically informed screening, precision management, delivery of genetic counselling or alternative genetic services and special considerations for men with prostate cancer.

    • Jessica Russo
    • Veda N. Giri
    Review Article
  • In this Review, the authors describe our current knowledge of the consequences of SARS-CoV-2 infection on the urogenital system, discussing urological symptoms and damage to organs of the genitourinary tract induced by COVID-19 infection. Moreover, the effects of COVID-19 on male fertility and sexual health are discussed.

    • Benedikt Ebner
    • Yannic Volz
    • Giuseppe Magistro
    Review Article
  • Active surveillance is recommended for low-risk and favourable intermediate-risk prostate cancer management, but active monitoring using imaging or biopsy is necessary to compensate for initial undergrading of the tumour or to detect early progression without missing the opportunity to provide curative therapy. In this Review, the authors discuss the potential for MRI-based active monitoring for active surveillance and consider how this approach might affect patient care.

    • Guillaume Ploussard
    • Olivier Rouvière
    • Raphaële Renard-Penna
    Review Article
  • Prognostic models incorporating clinical and pathological parameters might assist clinicians in counselling and surveillance of patients following surgical resection of renal cell carcinoma (RCC). Variability exists in the risk classification of individual patients in each model as well as the performance of each model in different RCC subtypes.

    • Thomas Gerald
    • Vitaly Margulis
    News & Views
  • Incidence and mortality disparities between males and females exist in many diseases including bladder cancer, but the mechanisms remain unclear. To adequately address this issue, researchers must design experiments appropriately, appreciate that sex and gender are not synonymous concepts and understand that the role of both sex and gender in disease need to be elucidated.

    • Dan Theodorescu
    • Zihai Li
    • Xue Li
  • The extent, duration and causes of alterations in the testes caused by SARS-CoV-2 are unclear. A new study has documented the effects of SARS-CoV-2 infection on the testes of a golden Syrian hamster model; however, the relevance of these findings to non-severe human infection is questionable.

    • Nathalie Dejucq-Rainsford
    News & Views
  • In this Review, Teoh et al. describe different mechanisms of early and late disease recurrence in non-muscle-invasive bladder cancer and discuss potential treatment options. In addition, the authors discuss the potential of molecular classification and treatment with immunotherapy and novel therapeutic agents in the future management of bladder cancer.

    • Jeremy Yuen-Chun Teoh
    • Ashish M. Kamat
    • Marek Babjuk
    Review Article